Overview

Comparison of Survival Benefit of Panitumumab With Supportive Care to Best Supportive Care Alone in Patients With Metastatic Colorectal Cancer

Status:
Completed

Trial end date:
2016-11-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the benefit of panitumumab in addition to best supportive care compared to best supportive care alone in patients with chemorefractory wild-type KRAS (Kirsten rat sarcoma viral oncogene homolog) metastatic colorectal cancer.

Phase:

Phase 3

Details

Lead Sponsor:

Amgen

Treatments:

Antibodies, Monoclonal
Panitumumab